1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Global Pharmaceutical Analysis & Statistics

Global Pharmaceutical Analysis & Statistics

Customer Support

Talk to Ahmad

+1 718 618 4302

Publishers

  • All
    • Firstword Pharma

All regions

1-30 of 30 reports

Dark Analytics: Shining a Torch for Pharma

  • $ 428
  • May 2018
  • 1 pages

Dark analytics can unlock a wealth of new clinical and commercial insights—but how can you make it work for you? Dark data and dark analytics have the potential to generate huge business insights, but ...

  • Advanced IT
  • Data Analytics
  • Pharmaceutical
  • World

Atopic Dermatitis: Update Bulletin #2 [March 2018]

  • $ 1151
  • March 2018
  • 1 pages

This edition presents key opinion leader (KOL) views on recent developments in the treatment of atopic dermatitis (AD). Topics covered include KOL views on; Pfizer’s announcement of initiation of the ...

  • Medical Biotechnology
  • Monoclonal Antibody
  • Pharmaceutical
  • Therapy
  • World

Nonalcoholic Steatohepatitis (NASH): Update Bulletin

  • $ 1151
  • February 2018
  • 1 pages

This edition presents the views and insights from three world leading key opinion leaders (KOLs) from North America and Europe on a variety of recent events in NASH market, including; Intercept Pharmaceuticals ...

  • Pharmaceutical
  • World
  • Product Initiative

COPD: Update Bulletin

  • $ 1151
  • January 2018
  • 1 pages

This edition presents the views and insights from three world leading key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the chronic obstructive pulmonary disease ...

  • Pharmaceutical
  • Therapy
  • Europe
  • North America
  • World

Alzheimer’s Disease: Update Bulletin [January 2018]

  • $ 1151
  • January 2018
  • 1 pages

This edition presents the views and insights from three world leading key opinion leaders (KOLs) from North America and Europe on a variety of recent events in Alzheimer’s disease (AD) market, including; ...

  • Dementia
  • Mental Health
  • Pathology
  • Pharmaceutical
  • World

Pricing and Reimbursement in Oncology -- Payer views

  • $ 2616
  • January 2018
  • 1 pages

As payer and stakeholder anger mounts, when will the oncology drug price bubble burst? Global cancer drug prices have increased by 10% every year between 1995 and 2013. That level of price inflation is ...

  • Oncology
  • Pharmaceutical
  • Therapy
  • United States
  • World

Cystic Fibrosis: Update Bulletin #3

  • $ 1151
  • December 2017
  • 1 pages

This edition presents world leading key opinion leader (KOL) views on recent developments in the cystic fibrosis (CF) space. Topics covered include; expert opinions on Vertex Pharmaceuticals’ regulatory ...

  • Antibiotic Resistance
  • Pharmaceutical
  • Therapy
  • United States
  • World

The ROI of Orphan Drugs-- Ensuring optimal returns (2017)

  • $ 792
  • December 2017
  • 1 pages

Orphan drugs are at the forefront of medical science and offer a chance for the pharma industry to make a real difference to people’s lives; there’s also the lure of potentially lucrative commercial ...

  • Pharmaceutical
  • Therapy
  • World

The Importance of Real World Evidence in Orphan Drugs

  • $ 770
  • November 2017
  • 1 pages

Proof of value is an imperative for orphan drug manufacturers: it’s the only route to improving patient access and overcoming unmet therapeutic needs for rare conditions. Progress has been made with ...

  • Pharmaceutical
  • Therapy
  • World

Commercialisaton of Biosimilars: Multifunctional teamwork for success

  • $ 2537
  • November 2017
  • 1 pages

Commercialisation of Biosimilars From bench to bedside, biosimilars continue to dominate boardroom discussions around the world. But after all the talking, what’s the secret to success in this high ...

  • Biosimilar
  • Medical Biotechnology
  • Pharmaceutical
  • World

Commercialisation of Biologics: Benchmarking leading players

  • $ 2537
  • October 2017
  • 1 pages

Commercialisation of Biologics: Benchmarking Leading Players It’s clear that the rapidly growing biologics sector holds a wealth of promise. The significant opportunities resulting from breaking new ...

  • Biopharmaceutical
  • Medical Biotechnology
  • Pharmaceutical
  • World

Biosimilars Real World Evidence: Proving the point

  • $ 2537
  • July 2017
  • 1 pages

Biosimilars Real World Evidence: Proving the point Biosimilar manufacturers face an uphill struggle to fully mobilise their product portfolio. Against a background of aggressive defence strategies by ...

  • Biopharmaceutical
  • Biosimilar
  • Medical Biotechnology
  • Pharmaceutical
  • World

Targeted Therapies in Asthma: KOL Insight: Update Bulletin [April 2017]

  • $ 1112
  • April 2017
  • 1 pages

This edition presents key opinion leader (KOL) views on recent developments in the targeted asthma treatment market Topics covered include; GlaxoSmithKline’s (GSK) presentation of new data at the American ...

  • Monoclonal Antibody
  • Pharmaceutical
  • Salicylic Acid
  • Therapy
  • World

Biosimilars Education: Addressing a significant unmet need

  • $ 2537
  • November 2016
  • 1 pages

Description How to educate stakeholders about biosimilar benefits What information and data do physicians, payers and patients need about biosimilars? benefits As the market expands and new therapeutic ...

  • Biopharmaceutical
  • Biosimilar
  • Medical Biotechnology
  • Pharmaceutical
  • World

Orphan Drugs: Pricing and Market Access Strategies

  • $ 770
  • October 2016
  • 1 pages

Description Orphan drug market access and pricing: strategies for success When it comes to securing market access and drug pricing for orphan drugs, a one size approach won’t work. Driven by increasing ...

  • Pharmaceutical
  • Therapy
  • European Union
  • United States
  • World

The Real Value of Medical Affairs

  • $ 428
  • September 2016
  • 1 pages

How to push Medical Affairs to the next level of effectiveness Are Medical Affairs (MA) teams doing enough to satisfy doctors? What specific improvements to information and interactions would elevate ...

  • Pharmaceutical
  • United States
  • World

Pharma Marketing 2020 (2016)

  • $ 770
  • January 2016
  • 1 pages

How can pharma marketing effectively meet future communication challenges in a rapidly changing market place? A shift in therapy decision making, the need for evidence to support brands and more informed ...

  • Advertising And Marketing
  • Marketing
  • Pharmaceutical
  • World
  • Demand

Commercial Excellence in Multichannel Marketing

  • $ 656
  • November 2015
  • 1 pages

Are you getting left behind your competitors in a multichannel marketing world? Your audience’s needs are changing. Are you delivering the right information, to the right people, at the right time, in ...

  • Advertising And Marketing
  • Marketing
  • Pharmaceutical
  • World

Drug Delivery - Innovations, trends, and their impact on pharma

  • $ 2337
  • November 2015
  • 1 pages

Why you need Drug Delivery - Innovations, trends, and their impact on pharma Revolutionary changes are disrupting the status quo simply through developments in the way drugs are given to patients. In ...

  • Drug Delivery
  • Pharmaceutical
  • World

Biosimilars: Regulatory Outlook

  • $ 2337
  • November 2015
  • 1 pages

Biosimilars offer a chance to improve access to, and reduce spending on, life-saving biologic therapies. But could regulators do more to support the market? While experts believe significant regulatory ...

  • Biosimilar
  • Medical Biotechnology
  • Pharmaceutical
  • World
  • Regulation

Clinical Trial Design for Commercial Success

  • $ 656
  • June 2015
  • 72 pages

Clinical Trial Design for Commercial Success offers expert insights on how to best position drugs for success through strategic innovative design of clinical trials. Clinical trials make up, on average, ...

  • Clinical Trial
  • Drug Development
  • Pharmaceutical
  • World

Physician Views: Can Intarcia's implantable GLP-1 treatment revolutionise the diabetes market?

  • $ 781
  • April 2015
  • 1 pages

Intarcia has previously suggested that it is the highest-valued privately owned biotech company in history. This claim is heavily built around the potential success of ITCA 650; a matchstick-sized, ...

  • Chronic Disease
  • Diabetes
  • Pharmaceutical
  • Therapy
  • World

Physician Views: The return of inhaled insulin – a paradigm shift or hard sell?

  • $ 781
  • February 2015
  • 1 pages

Sanofi is currently in the process of launching Afrezza in the US market. Afrezza is an inhaled insulin developed by MannKind, which was in-licensed by Sanofi last year. It is the first inhaled insulin ...

  • Insulin
  • Pharmaceutical
  • Therapy
  • World
  • Supply

Trends and Innovations in Drug Pricing

  • $ 656
  • January 2015
  • 1 pages

FirstWord’s Trends and Innovations in Drug Pricing report dissects international trends and examines how long-standing dynamics in competitive pricing and access will strengthen the payer position ...

  • Pharmaceutical
  • Therapy
  • United States
  • World

Optimal KOL Relationship Management -- Leveraging the digital approach

  • $ 656
  • November 2014
  • 1 pages

Every second of every minute of every day, new information is generated, disseminated, analysed and absorbed. For the pharmaceutical industry, there is the added pressure of pricing issues, ever-changing ...

  • Pharmaceutical
  • Europe
  • United States
  • World

Physician Views: Can Movantik revolutionise the opioid-induced constipation market?

  • $ 781
  • October 2014
  • 1 pages

It has been an eventful year for players operating in the US opioid-induced constipation (OIC) market. In June, the FDA recommended against requiring cardiovascular outcomes studies for all products ...

  • Opioid
  • Pharmaceutical
  • Therapy
  • World
  • Demand

Physician Views: Gilead's Phase III tenofovir alafenamide (TAF) data in HIV – an initial assessment

  • $ 781
  • October 2014
  • 1 pages

Following publication of the first Phase III data for Gilead Sciences' HIV therapy tenofovir alafenamide (TAF) on September 24, FirstWord is currently polling infectious disease specialists in the ...

  • Hepatitis Treatment
  • Pharmaceutical
  • Therapy
  • World
  • Forecast

Payer Insights: Hepatitis C

  • $ 7974
  • September 2014
  • 1 pages

The race is on for the company that can competitively price treatment regimens, share data on clinical benefit/positioning and support patient initiatives. Payer Insights: Hepatitis C, based on in-depth ...

  • Pharmaceutical
  • Therapy
  • United States
  • World

Physician Views: Are neurologists ready to embrace gene therapy?

  • $ 781
  • June 2014
  • 1 pages

As recently noted by Forbes, the biotech bull market of 2013 has helped to revive an approach to drug development that had become largely abandoned and pursued by only a few devoted believers. Between ...

  • Gene Therapy
  • Medical Biotechnology
  • Pharmaceutical
  • Therapy
  • World

Biosimilar Index: Tracking the Biosimilar Development Landscape

  • $ 5295
  • April 2014
  • 135 pages

FirstWord’s Biosimilar Index is a comprehensive drug intelligence service that provides a robust, dynamically updated and highly-detailed insight into the status of leading biosimilar and NCB assets ...

  • Biosimilar
  • Medical Biotechnology
  • Pharmaceutical
  • World



Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on